Chloroquine and Hydroxychloroquine Retinal Toxicity Consideration in the Treatment of COVID-19
Ruamviboonsuk, Paisan MD∗; Lai, Timothy Y. Y. MD, FRCOphth†; Chang, Andrew PhD, FRANZCO‡; Lai, Chi-Chun MD§; Mieler, William F MD¶; Lam, Dennis S. C. MD||,∗∗; for Asia-Pacific Vitreo-Retina Society
Abstract
The proposed doses of chloroquine (CQ) and hydroxychloroquine (HCQ) for treatment of COVID-19 (1000 mg/day for 10 days, CQ; 800 mg first day then 400 mg/day for 5 days, HCQ) in many guidelines worldwide, are considerably higher than the maximum recommended daily safe doses of both agents (≤2.3 mg/kg/day, CQ; ≤5.0 mg/kg/day, HCQ) for development of retinal toxicity. Irreversible retinal damage can occur if the exposure to the safe doses is >5 years. It is not known whether exposure to high doses over a short period of time can also cause the damage. We recommend that before prescribing CQ or HCQ, history of ocular disease should be obtained to avoid the prescription if appropriate. If either agent is to be used, routine baseline ocular examination is not absolutely necessary. Patients who do not have ocular disease should also be informed about the potential risk of retinal toxicity. Both agents, however, have not yet been proven to be beneficial to COVID-19.
-
Scientific Journal Publications
Effects of Switching to Aflibercept in Treatment Resistant Macular Edema Secondary to Retinal Vein Occlusion
Read moreSpooner K, Fraser-Bell S, Hong T, Chang A. Effects of Switching to Aflibercept in Treatment Resistant Macular Edema
-
Scientific Journal Publications
Chloroquine and Hydroxychloroquine Retinal Toxicity Consideration in the Treatment of COVID-19
Read moreRuamviboonsuk, Paisan MD∗; Lai, Timothy Y. Y. MD, FRCOphth†; Chang, Andrew PhD, FRANZCO‡; Lai, Chi-Chun MD§; Mieler, William
-
Scientific Journal Publications
Research
Read moreSydney Retina Clinic and Day Surgery is proud to be associated with a research department named the Sydney